Torralva Medical Therapeutics, LLC
Publicly observedPortland, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Portland | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Torralva Medical Therapeutics, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | VW2EHP9XKZ33 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2022Publicly observed
NIH SBIR/STTR award: Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.
USD 99,972.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2022Publicly observed
NIH SBIR/STTR award: Fentanyl induces naloxone-resistant vocal cord closure: target validation and development of opioid overdose treatments using a peer-reviewed animal model.
USD 446,782.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.